The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …

One of the principal biochemical characteristics of malignant cells compared to normal cells
is a metabolic switch from oxidative phosphorylation to increased glycolysis, even under …

Background Effective systemic therapies for patients with advanced, progressive
neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …

BACKGROUND An increased incidence of neuroendocrine tumors (NETs) has been
reported worldwide, but the reasons underlying this rise have not been identified. By …

Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has
shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We …

Purpose Everolimus improved median progression-free survival by 6.4 months in patients
with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the …

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …